# To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

> **NCT05388695** · PHASE1 · RECRUITING · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- 19 and 22+ B Cell Hematologic Tumors
- 19 and 20+ B Cell Hematologic Tumors

## Interventions

- **BIOLOGICAL:** Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells

## Key facts

- **NCT ID:** NCT05388695
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-08
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388695, "To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05388695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*